NCT00664716View on ClinicalTrials.gov

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

391

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Baminercept alfa 1

experimental - one dose level

BIOLOGICAL

Placebo

Placebo comparator

BIOLOGICAL

Baminercept alfa 2

experimental - second dose level

BIOLOGICAL

Baminercept alfa 3

experimental - third dose level

BIOLOGICAL

Baminercept alfa 4

experimental - fourth dose level

BIOLOGICAL

Baminercept alfa 5

experimental - fifth dose level

Trial Locations (8)

62270

Coordinating Research Site, Cuernavaca

87100

Coordinating Research Site, Torun

115522

Coordinating Research Site, Moscow

810112

Coordinating Research Site, Brăila

T4000AXL

Coordinating Research Site, San Miguel de Tucumán

04027-000

Coordinating Research Site, São Paulo

H2143

Coordinating Research Site, Budapest

LS7 4SA

Coordinating Research Site, Leeds

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00664716 - Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants | Biotech Hunter | Biotech Hunter